Shattuck Labs, Inc., a clinical-stage biotechnology company, reported a net loss of $48.8 million for the fiscal year ending December 31, 2025, a decrease from a loss of $75.4 million in the previous year. The company attributed this improvement to a significant reduction in research and development expenses, which fell by 47.5% to $35.3 million, primarily due to the discontinuation of the SL-172154 program and related workforce reductions. Total revenue for 2025 was $1 million, a stark decline from $5.7 million in 2024, which was largely due to the completion of obligations under collaboration agreements with Ono Pharmaceutical Co., Ltd. and ImmunoGen, Inc.
In terms of strategic developments, Shattuck Labs is advancing its lead product candidate, SL-325, a monoclonal antibody targeting the Death Receptor 3 (DR3) pathway, which is currently undergoing a Phase 1 clinical trial. The company expects to complete this trial by the second quarter of 2026 and initiate a Phase 2 trial for Crohn's Disease in the third quarter of 2026. Additionally, Shattuck is developing SL-425, a half-life extended version of SL-325, and exploring bispecific antibodies that target DR3 alongside other relevant therapeutic targets.
Operationally, Shattuck Labs employed 40 full-time staff as of December 31, 2025, with plans to expand its workforce to support clinical research and development efforts. The company has also made significant investments in its manufacturing capabilities, partnering with third-party contract manufacturers to ensure compliance with current Good Manufacturing Practices (cGMP). As of the end of 2025, Shattuck had $78.1 million in cash and cash equivalents, which it believes will fund operations into 2029, assuming full exercise of outstanding warrants.
Looking ahead, Shattuck Labs faces several risks, including the need for additional funding to support ongoing clinical trials and the potential for delays in product development due to regulatory hurdles or manufacturing challenges. The company has indicated that it may seek further capital through equity offerings or collaborations, but there is no guarantee that such funding will be available on favorable terms. The biotechnology sector's competitive landscape, characterized by rapid advancements and significant financial resources among larger firms, poses additional challenges to Shattuck's growth and market positioning.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a biotechnology company focused on developing innovative treatments for inflammatory and immune-mediated diseases. Its lead program, SL-325, is a high-affinity monoclonal antibody targeting the DR3 receptor to inhibit the TL1A pathway, aiming to treat conditions like IBD. The company leverages protein engineering, advances biologics into clinical trials, and collaborates with biopharma partners to create first-in-class immunotherapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.